GHRP-2 + CJC-1295
GHRP-2 + CJC-1295 is the high-output variant of the GHRH + GHRP family of stacks. Where CJC-1295 + Ipamorelin is the preferred protocol for long-term GH optimisation due to Ipamorelin's clean hormonal profile, GHRP-2 + CJC-1295 produces larger GH pulse amplitudes — making it relevant for research requiring maximal GH stimulus, intensive recovery phases, or short-term body composition interventions. The trade-off is moderate cortisol and prolactin co-stimulation at higher doses.
Stack Components
This blend combines 2 research peptides with complementary mechanisms designed to produce synergistic outcomes.
Synergy Rationale
GHRP-2 and CJC-1295 follow the same GHRH + GHRP synergy mechanism as the Ipamorelin version, but GHRP-2's greater intrinsic GHSR-1a potency produces a larger GH pulse when combined with the same CJC-1295 GHRH priming. Studies comparing GHRP-2 versus Ipamorelin in combination with GHRH analogues consistently show higher peak GH with GHRP-2.
GHRP-2 also acts at the hypothalamic level to suppress somatostatin (GH-inhibiting hormone), adding a second amplification mechanism to the pituitary-level action of CJC-1295. This dual-site synergy with CJC-1295's pituitary priming creates a very potent combined signal.
The cortisol elevation associated with GHRP-2 (particularly at doses above 200 mcg) is dose-dependent and transient. For short-term intensive protocols (4–6 weeks), this is generally considered acceptable. For long-term chronic use, the Ipamorelin version is preferred to avoid cumulative cortisol exposure.
Combined Mechanism of Action
GHRP-2 activates GHSR-1a receptors at both the hypothalamus (reducing somatostatin release) and the pituitary (directly triggering GH secretion). This dual action is partly responsible for its superior pulse amplitude versus Ipamorelin, which acts primarily at the pituitary level.
CJC-1295 amplifies the system by upregulating GH synthesis and filling the releasable pool via GHRH receptor activation. When GHRP-2 triggers the release pulse, a larger pool is available — producing larger amplitude.
The resulting GH pulses from this combination can be 5–10× the natural baseline amplitude, IGF-1 elevation is proportionally greater, and downstream body composition effects (lipolysis, protein synthesis) are correspondingly more pronounced than with Ipamorelin-based stacks.
Research Evidence
GHRP-2 has extensive human clinical data including diagnostic use. CJC-1295 has Phase 1/2 clinical data. The combination mechanism is well-characterised from individual compound research.
GHRP-2 Combined with GHRH Produces Synergistic GH Release
GHRP-2 combined with GHRH (1-29) produced GH pulses 3–5× larger than GHRH alone and significantly larger than GHRP-2 alone — confirming synergistic rather than additive interaction at the pituitary level.
Component Dosing Protocol
Dose cap GHRP-2 at 100–200 mcg to limit cortisol co-stimulation. Above 250 mcg, cortisol elevation becomes clinically significant. If planning a longer protocol (>8 weeks), switching to the Ipamorelin + CJC-1295 stack is recommended.
Safety Considerations
Reported Side Effects
- Cortisol elevation (dose-dependent)
- Prolactin increase (transient)
- Increased appetite (stronger than Ipamorelin)
- Water retention
- Tingling
- Injection site redness
Contraindications
- Active malignancy
- Inflammatory conditions (cortisol elevation risk)
- Anxiety disorders (cortisol amplification)
- Hypothyroidism
- Pregnancy
- Insulin resistance / diabetes
Frequently Asked Questions
Is GHRP-2 + CJC-1295 better than Ipamorelin + CJC-1295?
GHRP-2 + CJC-1295 produces larger GH pulses. Ipamorelin + CJC-1295 produces a cleaner hormonal response (no cortisol/prolactin elevation). For short-term maximum output protocols (4–6 weeks), GHRP-2 + CJC-1295 may produce superior body composition results. For long-term GH optimisation, Ipamorelin + CJC-1295 is safer and more sustainable.
What is the maximum recommended dose of GHRP-2 in this stack?
Most protocols cap GHRP-2 at 100–200 mcg per injection when combined with CJC-1295. Above 200 mcg, the cortisol co-stimulation becomes clinically significant without proportional GH benefit (the GH response plateaus due to somatotroph saturation). CJC-1295's priming effect means lower GHRP-2 doses produce larger pulses than GHRP-2 alone — maintaining the dose cap becomes more important, not less, with CJC-1295 added.
When should I choose this stack over CJC-1295 + Ipamorelin?
Choose GHRP-2 + CJC-1295 when: you have a specific short-term window (4–6 weeks) where maximum GH output is the priority (contest prep, intensive recovery from injury, short-term body recomposition sprint). Choose CJC-1295 + Ipamorelin when: you are running a long-term (8–16 week) protocol, when cortisol management is important (joint issues, inflammatory conditions, anxiety), or when sustained year-round GH optimisation is the goal.
Should cortisol be monitored on this stack?
Cortisol monitoring is recommended, particularly at higher GHRP-2 doses (150–200 mcg). Morning cortisol (8 AM fasted) provides a useful baseline. Significant cortisol elevation — beyond 20–25% above baseline — may indicate dose reduction or switching to Ipamorelin is warranted. Symptoms of elevated cortisol (sleep disruption, increased anxiety, weight gain especially around the midsection) should also trigger reassessment.
Can this stack be used for muscle building?
Yes — this is one of the primary research applications. GH pulses drive IGF-1 elevation, which promotes protein synthesis and muscle hypertrophy. GHRP-2 + CJC-1295's larger pulse amplitudes produce proportionally greater IGF-1 elevation compared to Ipamorelin-based stacks. When combined with resistance training and adequate protein intake, the anabolic environment supports accelerated lean mass gain.
Key Research References
- Bowers CY et al. (1997). Synergistic release of GH with GHRP-2 and GHRH combinations. J Endocrinol.
- Alba M et al. (2006). CJC-1295 in healthy adults. J Clin Endocrinol Metab.
Explore more peptide combination stacks
Browse All Blends →